HEИндивидуална стипендия2023–2026

Droscreeneuro · A drug screen for enhancers of adult neurogenesis in ageing: Drosophila as a new translationally-relevant platform

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период: 2023-09-01 → 2026-04-30
Финансиране от ЕС: 237 109 €
Участници: 7
Схема: HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Вещества и лекарства се тестват върху плодови мухи и човешки стволови клетки, за да се види дали стимулират създаването на нови неврони при стареене. Това помага за разработването на терапии, които да забавят когнитивния спад и подобрят качеството на живот на възрастните.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A drug screen for enhancers of adult neurogenesis in ageing: Drosophila as a new translationally-relevant platform

Ensuring a healthy lifespan in an increasingly ageing society is a global priority. In this context, generating knowledge and developing interventions to promote healthy ageing remains a major challenge for research and innovation. Irreversible neurodegenerative disorders are among the most detrimental age-related diseases and are increasingly prevalent in the elderly population. Alzheimer´s disease represents a paradigmatic case, where impairments degeneration of Olfactory Sensory Neurons (OSNs) precedes brain damage decades before. These pathologies impose a substantial socioeconomic burden—estimated at €800 billion annually in Europe—and severely compromise quality of life. Therefore, interventions that delay or counteract cognitive decline are urgently needed. Enhancing adult neurogenesis (AN)—the functional integration of new neurons into mature neural circuits—represents a promising strategy to mitigate age-related cognitive decline. While developed drugs to address these needs show efficacy in cells in vitro, often times they fail to exert an effect in vivo, thus demising final efficacy and increasing the costs of the drug development process. The main objective of this proposal, Droscreeneuro, is to establish a novel in vivo pipeline to identify compounds, including FDA- and EMA-approved drugs, that promote neuronal regeneration during ageing. This will be achieved using Drosophila and human induced pluripotent stem cells (hiPSCs) as translationally relevant experimental platforms. Ultimately, this work will provide a foundation for the development of therapies that promote healthy ageing, with significant scientific, economic, and societal impact.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Ensuring a healthy lifespan in an increasingly ageing society represents a priority and a challenge for research and innovation. Particularly, irreversible neurodegenerative conditions are becoming hallmarks in the elderly, imposing a severe socioeconomic burden and ultimately threatening quality of life. Promoting adult neurogenesis has the potential to rejuvenate neural circuits restoring cognitive functions. High-throughput models of adult neurogenesis can expedite the identification of mechanisms and compounds for the development of neuro-regenerative therapies. I have evidence for physiologic and drug-induced adult neurogenesis in the genetically conserved and highly tractable model Drosophila melanogaster. Here, I aim to i) characterize adult neurogenesis across Drosophila’s lifespan; ii) identify drugs promoting neurogenesis in ageing in vivo, using the Drosophila olfactory circuit as an experimental platform; iii) test primary drug hits for their potential to promote neurogenesis on hiPSC-NSC in vitro (Host: UGOE, DE; Secondments: MPI-CE, DE; Weizmann, IL; DZNE, DE). Next, during a Non-academic placement in a translational drug discovery company, I aim to profile prioritized hits promoting neuronal regeneration (LDC, DE). My unique background in chemical engineering and biosciences will be pivotal to successfully complete this project. By leveraging state-of-the-art tools and support from experts in the field, Droscreeneuro represents an innovative, ambitious, and translationally-relevant approach towards the development of regenerative therapies aimed at counteracting age-related neurodegenerative diseases. Dissemination of results between specialized and general audiences will make science open to all. Ultimately, exposure to high-quality training in the academic and non-academic sectors will substantially enhance my skills and career perspectives, to conduct research in academia and industry to promote society's wellbeing.

Оригинален текст от CORDIS (на английски).

Участници

GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS · GottingenКоординаторГермания
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV · BonnГермания
LEAD DISCOVERY CENTER GMBH · DortmundГермания
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENГермания
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS · GoettingenГермания
WEIZMANN INSTITUTE OF SCIENCE · RehovotИзраел
brainQr Therapeutics GmbH · GoettingenГермания